A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Indivi
This clinical trial studies a new screening program to improve the early detection of sporadic pancreatic cancer in individuals with a high risk of developing pancreatic cancer. Pancreatic cancer remains one of the deadliest solid tumors, characterized by a long phase without symptoms followed by rapid progression once
| Condition(s) | Pancreatic Ductal Adenocarcinoma |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | This clinical trial studies a new screening program to improve the early detection of sporadic pancreatic cancer in individuals with a high risk of developing pancreatic cancer. Pancreatic cancer remains one of the deadliest solid tumors, characterized by a long phase without symptoms followed by rapid progression once clinically evident. Despite advancements in treatment, the survival rate for pancreatic cancer remains low. Research has helped to identify a subset of individuals with a markedly high short-term risk for developing pancreatic cancer, which includes adults aged 50 and older with glycemically-defined new-onset diabetes and an Enriching New-Onset Diabetes for Pancreatic Cancer (ENDPAC) score ≥ 3. However, current practice guidelines do not provide clear pathways for surveillan |
| Who can participate | Inclusion Criteria: * Age ≥ 50 and ≤ 85 years * Glycemically-defined new-onset diabetes (gNOD) with onset ≤ 180 days preceding enrollment * Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC) score ≥ 3, based on validated risk stratification models * Provide written or remote informed consent Exclusion Criteria: * Prior diagnosis of pancreatic ductal adenocarcinoma (PDA) * Known hereditary cancer syndromes (e.g., BRCA1/2, Lynch syndrome, Peutz-Jeghers) * Prior history of pancreatic surgery * Pancreatic cyst surveillance at time of registration * Contraindications to contrast-enhanced CT imaging per standard clinical practice at time of registration |
| Ages | 50 Years to 85 Years |
| Sex | All |
| Lead sponsor | Mayo Clinic |
| Locations | Rochester, Minnesota, United States |
| Start date | 2026-03-24 |
| NCT ID | NCT07324096 |
| Official listing | https://clinicaltrials.gov/study/NCT07324096 |